Results Forecasts
Consolidated Earnings Forecasts
The following shows our consolidated earnings forecasts for fiscal year ending March 31, 2027. (Updated in August 2026)
(billions of yen)
| Results for the Fiscal Year Ended March 31, 2026 | fiscal year ending March 31, 2027 forecasts | Change | % change | |
|---|---|---|---|---|
| Net Sales | 500.0 | 545.0 | 45.0 | 9.0% |
| Operating Profit | 51.8 | 60.0 | 8.2 | 15.8% |
| Profit attributable to owners of the parent | 35.4 | 37.0 | 1.6 | 4.4% |
| Diluted earnings per share（yen） | 56.89 | 60.89 | 4.0 | 7.0% |
Sales Forecast By Destination
(billions of yen)
| Results for the Fiscal Year Ended March 31, 2026 | fiscal year ending March 31, 2027 forecasts | Change | % change | |
|---|---|---|---|---|
| Japan | 58.6 | 72.0 | 13.3 | 22.9% |
| Americas | 139.2 | 158.5 | 19.3 | 13.8% |
| EMEA | 158.0 | 176.0 | 18.0 | 11.4% |
| China | 89.4 | 76.5 | -12.9 | -14.5% |
| Asia-Pacific | 54.6 | 62.0 | 7.3 | 13.5% |
| Total | 500.0 | 545.0 | 45.0 | 9.0% |
- ※EMEA: Europe, Middle East, and Africa
Sales Forecast By Business
(billions of yen)
| Results for the Fiscal Year Ended March 31, 2026 | fiscal year ending March 31, 2027 forecasts | Change | % change | ||
|---|---|---|---|---|---|
| Diagnostics Business | Hematology | 299.4 | 325.0 | 25.5 | 8.5% |
| FCM | 4.6 | 7.5 | 2.8 | 59.9% | |
| Urinalysis | 44.0 | 49.0 | 4.9 | 11.2% | |
| Hemostasis | 72.4 | 74.0 | 1.5 | 2.2% | |
| Immunochemistry | 22.3 | 23.0 | 0.6 | 3.1% | |
| Clinical Chemistry | 2.9 | 13.0 | 10.0 | 345.7% | |
| Life Science | 24.9 | 24.0 | -0.9 | -3.8% | |
| Others | 25.9 | 24.0 | -1.9 | -7.5% | |
| Medical Robotics Business | 3.3 | 5.5 | 2.2 | 66.5% | |
| Total | 500.0 | 545.0 | 45.0 | 9.0% | |